Sanofi in United States — Immunology: the full competitive set, and the 2 AXLRx reports covering them with market-access, payer and competitive detail, every figure verified to a live source.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment.